上市3日持续净流入！高人气港股创新药精选ETF(520690)涨幅居前

Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug Selected ETF seeing a rise of 1.2% and notable increases in individual stocks such as Jingtai Holdings and Lepu Biopharma [1] - The Hong Kong Innovative Drug Selected ETF (520690) has attracted substantial capital since its listing on August 1, with a net inflow of 29.54 million yuan over the past three trading days, bringing its total size to 359 million yuan [1] - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, focusing on leading innovative drug companies listed in Hong Kong, including companies like BeiGene, Innovent Biologics, WuXi Biologics, and others [1] Group 2 - The innovative drug sector is expected to remain a core focus within the pharmaceutical industry, with sustained optimism regarding its growth and internationalization [2] - The industry is anticipated to benefit from ongoing policy support, enhancing global competitiveness and commercial profitability [2] - The upcoming adjustments in medical insurance catalogs and the promotion of commercial insurance policies are seen as important catalysts for the innovative drug sector in the second half of the year [1]